A Review of the Effects of Modafinil on Cognition in Schizophrenia
| Autor: | Barbara J. Sahakian, Danielle C. Turner, Sharon Morein-Zamir |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Psychosis
medicine.medical_specialty Methylphenidate Modafinil Cognition Neuropsychological Tests medicine.disease Executive functions Severity of Illness Index Psychiatry and Mental health Schizophrenia Theme: The Orexins/Hypocretins and Schizophrenia Ariel Y. Deutch mental disorders medicine Humans Cognitive skill Effects of sleep deprivation on cognitive performance Benzhydryl Compounds Cognition Disorders Psychology Psychiatry medicine.drug |
| Zdroj: | Schizophrenia Bulletin. 33:1298-1306 |
| ISSN: | 1745-1701 0586-7614 |
| DOI: | 10.1093/schbul/sbm090 |
| Popis: | Modafinil, a wake-promoting agent believed to operate via the hypocretin/orexin system, has a similar clinical profile to that of conventional, dopaminergic stimulants but different biochemical and pharmacological properties. There is increasing interest in the use of modafinil to improve cognition in schizophrenia as well as in other disorders such as attention-deficit/hyperactivity disorder. Recent research has focused on enhancing cognition in patients with schizophrenia because of the association between cognitive performance and functional outcome. Initial findings indicate that modafinil may lead to better executive functioning and attentional performance in patients with schizophrenia. The results further suggest that patient characteristics such as overall current cognitive functioning levels, genetic polymorphisms, and medication status may be important mediators for the effectiveness of modafinil, allowing for future treatment to be targeted to those most likely to benefit. Currently, further research is required to address the potential benefits and risks of chronic administration of modafinil to patients with schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|